603 related articles for article (PubMed ID: 30849534)
1. The relation between PI3K/AKT signalling pathway and cancer.
Noorolyai S; Shajari N; Baghbani E; Sadreddini S; Baradaran B
Gene; 2019 May; 698():120-128. PubMed ID: 30849534
[TBL] [Abstract][Full Text] [Related]
2. Class I PI3-kinase or Akt inhibition do not impair axonal polarization, but slow down axonal elongation.
Diez H; Benitez MJ; Fernandez S; Torres-Aleman I; Garrido JJ; Wandosell F
Biochim Biophys Acta; 2016 Nov; 1863(11):2574-2583. PubMed ID: 27421985
[TBL] [Abstract][Full Text] [Related]
3. PTEN/PTENP1: 'Regulating the regulator of RTK-dependent PI3K/Akt signalling', new targets for cancer therapy.
Haddadi N; Lin Y; Travis G; Simpson AM; Nassif NT; McGowan EM
Mol Cancer; 2018 Feb; 17(1):37. PubMed ID: 29455665
[TBL] [Abstract][Full Text] [Related]
4. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.
Martelli AM; Evangelisti C; Chappell W; Abrams SL; Bäsecke J; Stivala F; Donia M; Fagone P; Nicoletti F; Libra M; Ruvolo V; Ruvolo P; Kempf CR; Steelman LS; McCubrey JA
Leukemia; 2011 Jul; 25(7):1064-79. PubMed ID: 21436840
[TBL] [Abstract][Full Text] [Related]
5. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
[TBL] [Abstract][Full Text] [Related]
6. [Dermatological implications of the PI3K pathway].
Dereure O
Ann Dermatol Venereol; 2015 Oct; 142(10):622-3. PubMed ID: 26001484
[No Abstract] [Full Text] [Related]
7. PI3K/AKT Pathway and Its Mediators in Thyroid Carcinomas.
Nozhat Z; Hedayati M
Mol Diagn Ther; 2016 Feb; 20(1):13-26. PubMed ID: 26597586
[TBL] [Abstract][Full Text] [Related]
8. The role and therapeutic implications of PI3K signaling pathway in cancer.
Leiphrakpam PD; Chowdhury S; Wang J; Black JD; Are C
J Surg Oncol; 2021 Jan; 123(1):39-41. PubMed ID: 33179260
[No Abstract] [Full Text] [Related]
9. Specific gene expression signatures induced by the multiple oncogenic alterations that occur within the PTEN/PI3K/AKT pathway in lung cancer.
De Marco C; Laudanna C; Rinaldo N; Oliveira DM; Ravo M; Weisz A; Ceccarelli M; Caira E; Rizzuto A; Zoppoli P; Malanga D; Viglietto G
PLoS One; 2017; 12(6):e0178865. PubMed ID: 28662101
[TBL] [Abstract][Full Text] [Related]
10. PI3K/AKT/mTOR pathway is activated after imatinib secondary resistance in gastrointestinal stromal tumors (GISTs).
Li J; Dang Y; Gao J; Li Y; Zou J; Shen L
Med Oncol; 2015 Apr; 32(4):111. PubMed ID: 25757539
[TBL] [Abstract][Full Text] [Related]
11. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics.
Zhong H; Chiles K; Feldser D; Laughner E; Hanrahan C; Georgescu MM; Simons JW; Semenza GL
Cancer Res; 2000 Mar; 60(6):1541-5. PubMed ID: 10749120
[TBL] [Abstract][Full Text] [Related]
12. PI3K/PTEN signaling in tumorigenesis and angiogenesis.
Jiang BH; Liu LZ
Biochim Biophys Acta; 2008 Jan; 1784(1):150-8. PubMed ID: 17964232
[TBL] [Abstract][Full Text] [Related]
13. Regulation of PI3K effector signalling in cancer by the phosphoinositide phosphatases.
Rodgers SJ; Ferguson DT; Mitchell CA; Ooms LM
Biosci Rep; 2017 Feb; 37(1):. PubMed ID: 28082369
[TBL] [Abstract][Full Text] [Related]
14. Reconstitution of the mammalian PI3K/PTEN/Akt pathway in yeast.
Rodríguez-Escudero I; Roelants FM; Thorner J; Nombela C; Molina M; Cid VJ
Biochem J; 2005 Sep; 390(Pt 2):613-23. PubMed ID: 15913452
[TBL] [Abstract][Full Text] [Related]
15. PI3K/AKT signaling pathway and cancer: an updated review.
Martini M; De Santis MC; Braccini L; Gulluni F; Hirsch E
Ann Med; 2014 Sep; 46(6):372-83. PubMed ID: 24897931
[TBL] [Abstract][Full Text] [Related]
16. Targeting PI3K signalling in cancer: opportunities, challenges and limitations.
Engelman JA
Nat Rev Cancer; 2009 Aug; 9(8):550-62. PubMed ID: 19629070
[TBL] [Abstract][Full Text] [Related]
17. Contribution of PKB/AKT signaling to thyroid cancer.
Viglietto G; Amodio N; Malanga D; Scrima M; De Marco C
Front Biosci (Landmark Ed); 2011 Jan; 16(4):1461-87. PubMed ID: 21196242
[TBL] [Abstract][Full Text] [Related]
18. Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines.
Festuccia C; Muzi P; Millimaggi D; Biordi L; Gravina GL; Speca S; Angelucci A; Dolo V; Vicentini C; Bologna M
Endocr Relat Cancer; 2005 Dec; 12(4):983-98. PubMed ID: 16322337
[TBL] [Abstract][Full Text] [Related]
19. PI3K pathway alterations in cancer: variations on a theme.
Yuan TL; Cantley LC
Oncogene; 2008 Sep; 27(41):5497-510. PubMed ID: 18794884
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer.
Araki K; Miyoshi Y
Breast Cancer; 2018 Jul; 25(4):392-401. PubMed ID: 29086897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
